Jie Peng

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7625714/publications.pdf

Version: 2024-02-01

65	1,558	21 h-index	37
papers	citations		g-index
70	70	70	2174
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	aMAP Score as a Predictor for Long-Term Outcomes in Patients with HBV-Related Acute-on-Chronic Liver Failure. International Journal of General Medicine, 2022, Volume 15, 407-415.	0.8	4
2	A standardized assay for the quantitative detection of serum HBV RNA in chronic hepatitis B patients. Emerging Microbes and Infections, 2022, 11, 775-785.	3.0	7
3	Association of Serum Hepatitis B Virus RNA With Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Under Nucleos(t)ide Analogues Therapy. Journal of Infectious Diseases, 2022, 226, 881-890.	1.9	12
4	Soluble Programmed Cell Death-1 is a Novel Predictor of HBsAg Loss in Chronic Hepatitis B Patients When Long-Term Nucleos(t)ide Analog Treatment is Discontinued. Infection and Drug Resistance, 2022, Volume 15, 2347-2357.	1.1	3
5	Association between hypertension and prognosis of patients with COVID-19: A systematic review and meta-analysis. Clinical and Experimental Hypertension, 2022, 44, 451-458.	0.5	11
6	Immunogenicity and safety of an inactivated SARS oVâ€⊋ vaccine in people living with HIV: A crossâ€sectional study. Journal of Medical Virology, 2022, 94, 4224-4233.	2.5	13
7	A model for predicting high BMI of people living with HIV after receiving antiretroviral therapy. Therapeutic Advances in Chronic Disease, 2022, 13, 204062232211027.	1.1	1
8	Mean platelet volume/platelet count ratio predicts severe pneumonia of COVIDâ€19. Journal of Clinical Laboratory Analysis, 2021, 35, e23607.	0.9	33
9	Preoperative false-negative transthoracic echocardiographic results in native valve infective endocarditis patients: a retrospective study from 2001 to 2018. Cardiovascular Ultrasound, 2021, 19, 2.	0.5	3
10	Hepatitis B surface antigen kinetics after discontinuation of and retreatment with oral antivirals in nonâ€cirrhotic HBeAgâ€positive chronic hepatitis B. Journal of Viral Hepatitis, 2021, 28, 1121-1129.	1.0	7
11	Methodology-dependent performance of serum HBV RNA in predicting treatment outcomes in chronic hepatitis B patients. Antiviral Research, 2021, 189, 105037.	1.9	10
12	Thyroid dysfunction is associated with the loss of hepatitis B surface antigen in patients with chronic hepatitis B undergoing treatment with \hat{l}_{\pm} -interferon. Journal of International Medical Research, 2021, 49, 030006052110251.	0.4	2
13	Association of central obesity with hepatocellular carcinoma in patients with chronic hepatitis B receiving antiviral therapy. Alimentary Pharmacology and Therapeutics, 2021, 54, 329-338.	1.9	14
14	Serum hepatitis B virus RNA level is associated with biochemical relapse in patients with chronic hepatitis B infection who discontinue nucleos(t)ide analogue treatment. Alimentary Pharmacology and Therapeutics, 2021, 54, 709-714.	1.9	12
15	Combined procalcitonin and hemogram parameters contribute to early differential diagnosis of Gramâ€negative/Gramâ€positive bloodstream infections. Journal of Clinical Laboratory Analysis, 2021, 35, e23927.	0.9	11
16	TLR1/2 Agonist Enhances Reversal of HIV-1 Latency and Promotes NK Cell-Induced Suppression of HIV-1-Infected Autologous CD4 ⁺ T Cells. Journal of Virology, 2021, 95, e0081621.	1.5	10
17	Hepatitis B Core-Related Antigen is a Biomarker for off-Treatment Relapse After Long-Term Nucleos(t)ide Analog Therapy in Patients with Chronic Hepatitis B. International Journal of General Medicine, 2021, Volume 14, 4967-4976.	0.8	6
18	Association Between Nutritional Risk Screening Score and Prognosis of Patients with Sepsis. Infection and Drug Resistance, 2021, Volume 14, 3817-3825.	1.1	10

#	Article	IF	Citations
19	Clinical features of actinomycosis: A 20-year experience of a single institute in Southern China. Journal De Mycologie Medicale, 2021, 31, 101169.	0.7	3
20	Editorial: only steps away from primetime? Hepatitis B virus RNA as a routine marker to guide HBV treatment decisionsâ€"authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 54, 972-973.	1.9	0
21	Nomogram based on neutrophil-to-platelet ratio to predict in-hospital mortality in infective endocarditis. Biomarkers in Medicine, 2021, 15, 1233-1243.	0.6	6
22	Rapid Monitoring of Vancomycin Concentration in Serum Using Europium (III) Chelate Nanoparticle-Based Lateral Flow Immunoassay. Frontiers in Chemistry, 2021, 9, 763686.	1.8	7
23	Insufficient knowledge and inappropriate practices of emergency doctors towards tetanus prevention in trauma patients: a pilot survey. Human Vaccines and Immunotherapeutics, 2020, 16, 349-357.	1.4	5
24	CXCL13-mediated recruitment of intrahepatic CXCR5+CD8+ T cells favors viral control in chronic HBV infection. Journal of Hepatology, 2020, 72, 420-430.	1.8	62
25	Residual convolutional neural network for predicting response of transarterial chemoembolization in hepatocellular carcinoma from CT imaging. European Radiology, 2020, 30, 413-424.	2.3	127
26	Association Between Negative Results From Tests for HBV DNA and RNA and Durability of Response After Discontinuation of Nucles(t)ide Analogue Therapy. Clinical Gastroenterology and Hepatology, 2020, 18, 719-727.e7.	2.4	72
27	Genetic variations in the CXCR5 gene decrease the risk of clinical relapse after discontinuation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B. Infection, Genetics and Evolution, 2020, 78, 104124.	1.0	4
28	Platelet microparticlesâ€derived miRâ€25â€3p promotes the hepatocyte proliferation and cell autophagy via reducing Bâ€cell translocation gene 2. Journal of Cellular Biochemistry, 2020, 121, 4959-4973.	1.2	5
29	Generation of sphingosine-1-phosphate by sphingosine kinase 1 protects nonalcoholic fatty liver from ischemia/reperfusion injury through alleviating reactive oxygen species production in hepatocytes. Free Radical Biology and Medicine, 2020, 159, 136-149.	1.3	10
30	Association Between Clinical Manifestations and Prognosis in Patients with COVID-19. Clinical Therapeutics, 2020, 42, 964-972.	1.1	55
31	Combining Hepatitis B Virus RNA and Hepatitis B Core–Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen–Positive Patients With Chronic Hepatitis B. Journal of Infectious Diseases, 2020, 222, 611-618.	1.9	50
32	Patients with tuberculous meningitis and hepatitis B co-infection have increased risk for antituberculosis drug-induced liver injury and poor outcomes. Infectious Diseases, 2020, 52, 793-800.	1.4	5
33	<p>Serum Hepatitis B Virus RNA Levels Predict HBeAg Seroconversion and Virological Response in Chronic Hepatitis B Patients with High Viral Load Treated with Nucleos(t)ide Analog</p> . Infection and Drug Resistance, 2020, Volume 13, 1881-1888.	1.1	15
34	Longitudinal Change of Body Mass Index Is Associated With Alanine Aminotransferase Elevation After Complete Viral Suppression in Chronic Hepatitis B Patients. Journal of Infectious Diseases, 2019, 220, 1469-1476.	1.9	7
35	Intestinal Microbiota Can Predict Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1944-1955.	2.0	38
36	Elevated expression of serum soluble ST2 in clinical relapse after stopping long-term Nucleos(t)ide analogue therapy for chronic hepatitis B. BMC Infectious Diseases, 2019, 19, 640.	1.3	4

#	Article	IF	Citations
37	Reply. Clinical Gastroenterology and Hepatology, 2019, 17, 1001-1002.	2.4	O
38	Circulating miR-122 Is a Predictor for Virological Response in CHB Patients With High Viral Load Treated With Nucleos(t)ide Analogs. Frontiers in Genetics, 2019, 10, 243.	1.1	10
39	A changing profile of infective endocarditis at a tertiary hospital in China: a retrospective study from 2001 to 2018. BMC Infectious Diseases, 2019, 19, 945.	1.3	9
40	Plasma CXCL13 is a predictive factor for HBsAg loss and clinical relapse after discontinuation of nucleos(t)ide analogue treatment. Clinical Immunology, 2019, 198, 31-38.	1.4	10
41	Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated With Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy. Clinical Gastroenterology and Hepatology, 2019, 17, 182-191.e1.	2.4	53
42	A GUT Microbiota Score Predicting for ACUTE GRAFT-Versus-Host Disease. Blood, 2019, 134, 1991-1991.	0.6	0
43	Risk factors associated with liver steatosis and fibrosis in chronic hepatitis B patient with component of metabolic syndrome. United European Gastroenterology Journal, 2018, 6, 558-566.	1.6	49
44	Increased mediator complex subunit 15 expression is associated with poor prognosis in hepatocellular carcinoma. Oncology Letters, 2018, 15, 4303-4313.	0.8	5
45	A radiomics nomogram for preoperative prediction of microvascular invasion risk in hepatitis B virus-related hepatocellular carcinoma. Diagnostic and Interventional Radiology, 2018, 24, 121-127.	0.7	142
46	Serum hepatitis B core antibody levels predict HBeAg seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs. Infection and Drug Resistance, 2018, Volume 11, 469-477.	1.1	39
47	A noninvasive diagnostic model to assess nonalcoholic hepatic steatosis in patients with chronic hepatitis B. Therapeutic Advances in Gastroenterology, 2017, 10, 207-217.	1.4	38
48	Impaired expression and function of TLR8 in chronic HBV infection and its association with treatment responses during peg-IFN- \hat{l} ±-2a antiviral therapy. Clinics and Research in Hepatology and Gastroenterology, 2017, 41, 386-398.	0.7	22
49	Denoise diffusion-weighted images using higher-order singular value decomposition. Neurolmage, 2017, 156, 128-145.	2.1	33
50	Off-Treatment Hepatitis B Virus (HBV) DNA Levels and the Prediction of Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B: A Prospective Stop Study. Journal of Infectious Diseases, 2017, 215, 581-589.	1.9	52
51	Durability of Response After Hepatitis B Surface Antigen Seroclearance During Nucleos(t)ide Analogue Treatment in a Multiethnic Cohort of Chronic Hepatitis B Patients: Results After Treatment Cessation. Clinical Infectious Diseases, 2017, 65, 680-683.	2.9	30
52	Improved Liver R2* Mapping by Averaging Decay Curves. Scientific Reports, 2017, 7, 6158.	1.6	2
53	Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update). Journal of Clinical and Translational Hepatology, 2017, 5, 297-318.	0.7	181
54	Elevated Expression of Chemokine CXCL13 in Chronic Hepatitis B Patients Links to Immune Control during Antiviral Therapy. Frontiers in Immunology, 2017, 8, 323.	2.2	14

#	Article	IF	CITATIONS
55	Lower Expression of MicroRNA-155 Contributes to Dysfunction of Natural Killer Cells in Patients with Chronic Hepatitis B. Frontiers in Immunology, 2017, 8, 1173.	2.2	24
56	Combining routine markers improves the accuracy of transient elastography for hepatitis B cirrhosis detection. Digestive and Liver Disease, 2016, 48, 512-518.	0.4	11
57	Potential effects of telbivudine and entecavir on renal function: a systematic review and meta-analysis. Virology Journal, 2016, 13, 64.	1.4	38
58	Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result. Clinical and Experimental Medicine, 2016, 16, 429-436.	1.9	48
59	Effect of preemptive local injection of ropivocaine with dexmedetomidine on mirror pain in rats and its mechanism. Asian Pacific Journal of Tropical Medicine, 2015, 8, 836-840.	0.4	1
60	Factors associated with adherence to nucleos(t)ide analogs in chronic hepatitis B patients: results from a 1-year follow-up study. Patient Preference and Adherence, 2015, 9, 41.	0.8	22
61	Predictors of sustained virologic response after discontinuation of nucleos(t)ide analog treatment for chronic hepatitis B. Saudi Journal of Gastroenterology, 2015, 21, 245.	0.5	16
62	Dynamic comparison between Daan real-time PCR and Cobas TaqMan for quantification of HBV DNA levels in patients with CHB. BMC Infectious Diseases, 2014, 14, 85.	1.3	38
63	Non-invasive assessment of liver fibrosis in patients with chronic hepatitis B. Hepatology International, 2013, 7, 356-368.	1.9	22
64	Clinical and histological characteristics of chronic hepatitis B with negative hepatitis B e-antigen. Chinese Medical Journal, 2003, 116, 1312-7.	0.9	5
65	Construction of recombinant eukaryotic expression plasmid containing hepatitis B virus genome with partial deletion of the core promoter. Di 1 Jun Yi Da Xue Xue Bao = Academic Journal of the First Medical College of PLA, 2001, 21, 806-808.	0.1	O